BrainChild Bio
BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system tumors, spun out of Seattle Children's in 2023 to prioritize pediatric brain tumors, primarily DIPG, with planned expansion into adult glioblastoma and brain metastases.
- Company typePrivate
- Founded2023
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BrainChild Bio does
BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for tumors of the central nervous system, with a pediatric-first pipeline anchored by lead candidate BCB-276 in diffuse intrinsic pontine glioma (DIPG), an incurable childhood brainstem cancer. The company was launched in December 2023 as a spin-off from Seattle Children's, founded by Dr. Michael Jensen — inventor of over 200 cell and gene therapy patents and co-founder of Juno Therapeutics and Umoja Biopharma — and is led by CEO Steven Brugger (formerly CEO of Affinivax, acquired by GSK for $3.3 billion in 2022).
The company's core technology is a unified CAR-T platform built on three proprietary pillars: (1) recursive intracerebroventricular dosing that delivers CAR-T cells directly into the cerebrospinal fluid, bypassing the blood-brain barrier and eliminating the need for systemic lymphodepleting chemotherapy; (2) a multiplexed targeting portfolio against EGFR, HER2, B7-H3, and IL13Ralpha2 designed to prevent therapeutic failure from antigen escape; and (3) the PotencyPlus synthetic transgene library that augments CAR-T potency in the immunosuppressive tumor microenvironment. Beyond lead candidate BCB-276, the pipeline includes BCB-214 (PotencyPlus-enhanced, near-term Phase I) and additional clinical candidates BrainChild-01 through BrainChild-04 targeting HER2, B7-H3, and a quad-targeting construct.
BrainChild Bio is pre-revenue and generates no commercial product sales today. Its economics are entirely clinical-development-stage: it funds operations through grants (e.g., a $300,000 ScaleReady G-Rex Grant in January 2025) and is positioned to monetize via commercialization of CAR-T products following FDA approval. It received FDA Breakthrough Therapy Designation in April 2025 and RMAT designation in May 2025 for its B7-H3 program, enabling an expedited pivotal registrational pathway toward BLA. The company is headquartered in Seattle with a secondary presence at the Cambridge Innovation Center, operates with 11–50 employees, and its primary customers — once commercialized — will be pediatric patients with DIPG/DMG and, on pipeline extension, adult patients with glioblastoma and brain metastases.
BrainChild Bio firmographics
Firmographics- Name
- BrainChild Bio
- Legal name
- BrainChild Bio, Inc.
- Website
- https://brainchildbio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system tumors, spun out of Seattle Children's in 2023 to prioritize pediatric brain tumors, primarily DIPG, with planned expansion into adult glioblastoma and brain metastases.
- Ownership category
- akta.pro rank
BrainChild Bio industry classification
Industry- Product category
- Cell Therapy / CAR-T Immunotherapy for CNS Tumors
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Neuro-oncology (HLAKAIAL)
Keywords
Where BrainChild Bio is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BrainChild Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- CAR-T Therapy Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing CAR T-cell therapies for CNS tumors. Revenue will be generated through commercialization of proprietary cell therapy products following FDA approval. BCB-276 is the lead candidate for DIPG with pivotal trial pathway aligned with FDA.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
BrainChild Bio product offering
Product offeringCore offering
BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system (CNS) tumors, with lead candidate BCB-276 (an autologous B7-H3-targeting CAR T-cell therapy) advancing toward a pivotal registrational trial for diffuse intrinsic pontine glioma (DIPG). The platform uses recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed CAR targeting and the proprietary PotencyPlus transgene, addressing both pediatric brain tumors and adult CNS indications including glioblastoma and brain metastases.
Product overview
BrainChild Bio is a clinical-stage biotechnology company developing a unified CAR T-cell therapy platform for central nervous system (CNS) tumors. The platform centers on recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed targeting CARs (BCB-276, BCB-214, and clinical candidates BrainChild-01 through BrainChild-04) targeting antigens including B7-H3, HER2, EGFR, and IL13Ralpha2. Lead candidate BCB-276 is an autologous B7-H3 targeting CAR T-cell therapy advancing toward a pivotal registrational trial for DIPG, while BCB-214 incorporates the proprietary PotencyPlus transgene for enhanced potency. The pipeline prioritizes pediatric brain tumors with planned expansion to adult indications including glioblastoma and brain metastases.
Differentiator
Problem solved
Functional benefit
Products and services
- BCB-276 Autologous B7-H3 targeting CAR T-cell therapy for treating diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. The therapy uses recursive intracerebroventricular dosing to bypass the blood-brain barrier and deliver potent, persistent anti-tumor effector cells. Lead candidate for BrainChild Bio, advancing toward a pivotal registrational trial following FDA Breakthrough Therapy and RMAT designations.
- BCB-214 CAR-T cell therapy candidate incorporating the PotencyPlus synthetic transgene to enhance immune cell potency and counteract the immunosuppressive tumor microenvironment. Designed for near-term Phase I testing.
- BrainChild-01 (HER2-targeting CAR-T) HER2-targeting CAR T-cell therapy for CNS tumors, with results published in Nature Medicine. One of multiple single-target CAR-T candidates in the company's clinical portfolio targeting CNS tumors.
- BrainChild-03 (B7-H3-targeting CAR-T) B7-H3-targeting CAR T-cell therapy with results published in Cancer Discovery. Part of the company's multiplexed targeting strategy to overcome tumor heterogeneity and antigen escape in CNS tumors.
- BrainChild-04 (Quad-targeting CAR-T) Quad-targeting CAR-T cell therapy using multiple tumor-associated antigens (EGFR, HER2, B7-H3, IL13Ralpha2) to minimize therapeutic failures from antigen escape variants, representing the company's multiplexed targeting approach to CNS tumors.
Quantifiable outcome
- Phase 1 trial completed with excellent safety and tolerability outcomes for B7-H3 targeting CAR T-cell therapy
- +1 more outcomes
Companies that use BrainChild Bio
Customer profileSegments2 records
Ideal customer profiles2 records
BrainChild Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BrainChild Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Seattle Children's HospitalcoreSeattle Children's launched BrainChild Bio in December 2023 to accelerate CAR T-cell therapies for children with brain tumors. Dr. Nicholas Vitanza serves as CNS CAR T-cell Lead and DIPG Research Lead at Seattle Children's, and Dr. Michael Jensen previously served as founding Chief Therapeutics Officer at Seattle Children's Therapeutics.
- Send It FoundationminorBrainChild Bio supports Send It Foundation, which provides transformative outdoor adventures for young adults facing cancer. The partnership reflects the company's commitment to supporting young cancer survivors beyond the lab.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
BrainChild Bio competitors and assessment
Company assessmentOthers
- Affinivax (acquired by GSK): Previous company of BrainChild CEO Steven Brugger, acquired by GSK for $3.3B in 2022; relevant as the benchmark exit profile of BrainChild's CEO and as a vaccine/biological products comparable rather than direct CAR-T competitor.
Emerging players
- Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies; comparable as a small-cap clinical-stage CAR-T developer facing similar regulatory, manufacturing, and capital-raise challenges.
- Precision BioSciences: Clinical-stage cell therapy company developing allogeneic CAR-T candidates using ARCUS gene editing; comparable as a clinical-stage CAR-T platform with similar early-stage profile and pipeline diversification strategy.
- Cabaletta Bio: Clinical-stage cell therapy company developing CAR-T candidates with novel engineering approaches; comparable as a similarly-sized early clinical-stage CAR-T platform company pursuing indications with high unmet need.
Regional players
- Carsgen Therapeutics: China-based clinical-stage CAR-T developer with solid tumor pipeline including CNS indications; comparable as a CAR-T platform competitor pursuing overlapping indications, though primarily operating in Asia.
Direct peers
- Tessa Therapeutics: Clinical-stage cell therapy company developing CAR-T therapies for solid tumors including CNS malignancies; directly comparable as a CAR-T developer targeting solid tumors with similar regulatory and clinical validation requirements.
- Mustang Bio: Clinical-stage cell therapy company developing CAR-T therapies, including for glioblastoma and other brain tumors; directly comparable as a small-cap CAR-T developer targeting CNS malignancies with similar regulatory and capital challenges.
- Umoja Biopharma: Co-founded by BrainChild founder Dr. Michael Jensen, Umoja is developing in vivo CAR-T platform technologies; comparable as a Jensen-originated CAR-T platform company at similar early-clinical stage with shared scientific lineage.
Broad incumbents
- Novartis: Markets Kymriah, the first FDA-approved CAR-T therapy; comparable as the established CAR-T incumbent whose pediatric and solid tumor expansion ambitions create both competitive threat and potential partnership/liquidity opportunity for BrainChild.
- Bristol Myers Squibb (Juno Therapeutics): BMS acquired Juno Therapeutics (co-founded by BrainChild's Dr. Jensen) and markets Breyanzi and Abecma CAR-T therapies; comparable as the broader CAR-T commercial leader and the most direct commercialization reference for Jensen-originated cell therapy platforms.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BrainChild Bio social profiles
Digital presenceBrainChild Bio compliance and trust
Trust signalCompliance3 records
BrainChild Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainChild Bio leadership team
Management profileNumber of profiles
Profiles10 records
BrainChild Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainChild Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainChild Bio
What does BrainChild Bio do?
BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system (CNS) tumors, with lead candidate BCB-276 (an autologous B7-H3-targeting CAR T-cell therapy) advancing toward a pivotal registrational trial for diffuse intrinsic pontine glioma (DIPG). The platform uses recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed CAR targeting and the proprietary PotencyPlus transgene, addressing both pediatric brain tumors and adult CNS indications including glioblastoma and brain metastases.
Is BrainChild Bio a public or private company?
BrainChild Bio is a private company. It is classified as unknown and is currently operating.
When was BrainChild Bio founded?
BrainChild Bio was founded in 2023. It employs 11 to 50 people.
Where is BrainChild Bio based?
BrainChild Bio is headquartered in Seattle, United States, in the North America region.
How does BrainChild Bio make money?
One revenue line is on record: CAR-T Therapy Development and Commercialization.
Who are BrainChild Bio's main competitors?
Affinivax (acquired by GSK) is listed as an others. Emerging players are Caribou Biosciences, Precision BioSciences and Cabaletta Bio. Carsgen Therapeutics is listed as a regional player. Direct peers are Tessa Therapeutics, Mustang Bio and Umoja Biopharma. Broad incumbents are Novartis and Bristol Myers Squibb (Juno Therapeutics).
Does BrainChild Bio have an API?
No public API is recorded for BrainChild Bio.
What industry is BrainChild Bio in?
BrainChild Bio's product category is Cell Therapy / CAR-T Immunotherapy for CNS Tumors. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.